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Figure 1. Acute and chronic GVHD
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allogeneic transplantation targeting Tcell depletion, with the
goal of decreasing the incidence and severity of both acute
and chronic GVHD. This is an update to the previously pub-
lished data where we showed that lower ATG dose resulted
in improved non-relapse mortality and infection rate
without compromising control of GVHD.
Methods: We retrospectively analyzed 136 consecutive
patients who received RIC HSCT between 2006 and 2010.
Following October 2007, ATG dosing was lowered from 7.5
mg/kg (R-ATG) to 6 mg/kg (r-ATG). Progression-free (PFS)
and overall survival (OS) were analyzed using the log-rank
test. Cumulative incidences of GVHD were analyzed using
Gray's test, accounting for competing risks.
Results: Thirty-nine patients received R-ATG and 97 received
r-ATG. There were no signiﬁcant differences in age, gender,
KPS, degree of HLA match, prior autografts, donor/recipient
CMV status, and CD34 cell dose between the two groups (P>
.15). More patients were transplanted with r-ATG than R-ATG
for CLL and fewer with AML/MDS/NHL/HD/other histologies
(P ¼ .02). Time to platelet engraftment as well as donor-cell
chimerism at days +30, +90, +180 were not signiﬁcantly
different between the groups, but time to neutrophil
engraftment was shorter with R-ATG (P ¼ .001). Proportions
of aGVHD II-IV were 52% and 41% (P ¼ .34) in r-ATG and
R-ATG respectively and proportions of cGVHD were 40% and
53% (P ¼ .23). Further, no signiﬁcant differences in the
cumulative incidence of GVHDwere observed (Figure 1). The
R-ATG group experienced more episodes of bacterial
infections than the r-ATG cohort (54% vs. 8%; P < .0001).
No differences in PFS (P ¼ .69) or OS (P ¼ .95) were
observed between the cohorts.
Conclusion: r-ATG did not result in an increase incidence of
acute or chronic GVHD. No PFS or OS differences were
observed between the cohorts; however, R-ATG resulted in
a higher proportion of bacterial infections.392
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Background: Chronic graft vs. host disease (cGVHD) is
a major cause of morbidity and mortality after allogeneic
HSCT. As an insidious onset and heterogeneous presentation
renders this disease difﬁcult to diagnose, there is a need for
validated diagnostic biomarkers. Previously, soluble amino-
peptidase N (CD13) was identiﬁed in a pediatric study as
a biomarker for early onset cGVHD (diagnosed 3-9 months
post transplant). Aminopeptidase N is a protease involved in
immunoregulation on several levels; functions include
attraction of T cells, antigen presentation, facilitation of
adhesion and phagocytosis. Although it is integrated in the
membrane of several cell types it can also be cleaved into
soluble aminopeptidase N. In this study, we tested the
potential plasma biomarker soluble aminopeptidase N in an
adult population of late onset cGVHD patients using botha targeted method (enzymatic assay) as well as a non-tar-
geted approach (proteomics).
Methods: Samples used in this study were frozen, EDTA-
treated plasma samples derived from a single institution
participating in the Chronic GVHD Consortium and consisted
of 17 cases and 21 time-matched controls, all from adult
patients. Cases were within 1 month of diagnosis of late-
onset cGVHD (onset >9 months post transplant). Time
posttransplant for cases vs. controls was 12 (9.2-26.8) vs. 11.9
(5.3-13.5) months, respectively. Other potential clinical
variables included age at sample collection, gender, graft
source, donor type, conditioning intensity, prior acute grade
II-IV GVHD, and months from sample collection. Amino-
peptidase N activity was determined by cleavage of
L-leucine-p-nitroaniline; quantitative proteomic analyses
were done with iTRAQ.
Results and Conclusions: Plasma from cGVHD patients had
signiﬁcantly higher mean levels of aminopeptidase N
enzyme activity than did plasma from control patients (0.30
vs. 0.18 mU/ml, respectively P ¼ .0008). Proteomic analyses
using the same samples revealed that this difference was not
restricted to activity; aminopeptidase N showed the most
signiﬁcant difference in protein levels corresponding to
presence or absence of cGVHD of all the proteins identiﬁed.
Relative amounts of soluble aminopeptidase N were 1.44 vs.
0.9, in cases and controls, respectively (P¼ .0042). This study
supports soluble aminopeptidase N as a potential diagnostic
biomarker in adult GVHD. These results will be validated in
a larger population which also includes early onset cGVHD.393
Long-Term Survival After Allogeneic Haematopoietic Cell
Transplantation for Acute Myeloid Leukemia.
Comparable Results From Myeloablative and Non-
Myeloablative Conditioning in Young and Elderly Patients
Henrik Sengelov 1, Thomas Gerds 2, Peter Braendstrup 3,
Brian Kornblit 3, Bo Kok Mortensen 3, Soren Petersen 1,3,
Lars Vindeloev 1,3. 1 Department of Hematology L, National
University Hospital, Rigshospitalet, Copenhagen, Denmark;
2Department of Biostatistics, University of Copenhagen,
Denmark; 3Department of Hematology L, The Allo-HCT
laboratory, Copenhagen, Denmark
Nonmyeloablative (NM) conditioning in allogeneic
transplantation is increasingly used in patients aged over 50
years with acute myeloid leukemia (AML). In this single-
center retrospective study, we report the results of NM and
myeloablative (MA) conditioning in 207 consecutive AML
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plus 2 Gy TBI, while MA conditioning was cyclophosphamide
120 mg/m2 in combination with 12 Gy TBI or 12.8 mg/kg
busilvex. MA conditioning was given to 122 patients and NM
to 85 patients. Median age at transplant was 39 (range 15-56)
in MA patients and 59 (range 27-73) in NM patients. Donor
source, cytogenetic risk, CMV antigen status recipient/donor,
sex match, Karnofsky score, and body mass index were not
different among MA and NM patients. Disease stages CR1,
CR2, and >CR2/Primary Induction Failure (PIF) were
analyzed separately. Survival of patients with advanced stage
(>CR2/PIF) was short in both groups; 6.1 and 5.2 months in
MA and NM, respectively. Patients in CR1 and CR2 were
analyzed in details. Patient numbers in MA and NM trans-
plants were 60 vs. 62 in CR1 and 50 vs. 17 in CR2. In CR1 and
CR2 MA patients 68% and 48% received bone marrow,
whereas all of the NM patients received peripheral stem
cells, P < .001. Day 100 TRM in MA vs. NM transplants was
8.3% vs. 1.6% in CR1patients and 14% vs. 5.9% in CR2 patients,
which was not signiﬁcantly different. Relapse incidence was
comparable among the MA and NM transplants, both in CR1
and CR2 patients. The cumulative incidence of relapse at 1
year was 18.4% (CI: 5.0-28.2) versus 20.9% (CI: 5.2-31.1) inMA
and NM patients transplanted in CR1, and 14.5% (CI: 5.1-24.5)
versus 11.8% (CI: 0- 27.1) in CR2 patients (n.s.). The 5 year
overall survival (OS) probability in the CR1 patients with MA
conditioning vs NM conditioning was 63.9% (CI:51.4-76.4) vs
64.0% (CI:51.4-76.6), and among CR2 patients 51.2% (CI:36.0-
66.4) vs 64.7 (CI:41.9-87.4), (n.s.). The median survival
follow-up time was 55 months (range: 9-137) among CR 1
patients, and 54 months (range: 7-133) among CR2 patients.
The 3-year cumulative incidence of chronic GVHD in CR1
patients was 52.8% (CI:39.9-65.8) and 41.9% (CI:29.3-54.7) in
MA and NM patients, respectively. In CR2 patients, the inci-
dences were 32.7% (CI:19.0-46.3) and 41.2% (CI:17.8-64.6). In
conclusion, OS, TRM and relapse in NM transplants were
comparable to MA transplants despite a truly NM regimen
and a substantial age difference between groups.Figure 1. OS by Second HCT for Patients with Post-HCT Relapse394
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Background: Relapse is the primary cause of treatment
failure after alloHCT for hematologic malignancies. We
describe the presentation, management, and outcomes of
childrenwith post-HCT relapse, speciﬁcally focusing on post-
HCT minimal residual disease (MRD), to improve monitoring
and intervention strategies.
Design: This was a single institution, retrospective cohort
study of children with relapse or progression of acute
lymphoblastic leukemia (ALL), acute myelogenous leukemia
(AML), mixed phenotypic acute leukemia (MPAL) or myelo-
dysplastic syndrome (MDS) post-alloHCT between January 1,
2003 and December 31, 2010. MRD was deﬁned as disease
detectable by immunophenotypic, cytogenetic or molecular
methods that did not meet classic morphologic criteria for
relapse (deﬁned as 5% disease). Relapse was deﬁned as any
evidence for disease detected after previously negativeresults, includingMRD. Progressive diseasewas deﬁned as an
increase in any measure from baseline results.
Results: 40 of 93 (43%) patients who underwent a ﬁrst
alloHCT experienced relapse, including patients with AML
(n¼18), ALL (n¼16), MPAL (n¼4) andMDS (n¼2). Themedian
time from alloHCT to relapse was 144 days (range 1 month-
58 months). Nine patients with post-HCT MRD as the ﬁrst
evidence for relapse, presented at a median time of 35 days
post-HCT (range 28-182 days), with the majority having
rapid progression of disease. Median survival after relapse
was 123 days (range 4 days-5 years). Estimated 6-month and
1-year post-relapse survival was 30% and 17.5%, respectively.
Five of 40 (12.5%) patients are currently alive with a median
follow-up of 39 months, including 1 patient with active
disease. 1 survivor had MDS and presented with MRD alone.
The remaining 4 (with leukemia) presented with overt
disease between 146 and 411 days post-HCT. 3 of 5 survivors
underwent a second HCT. 11 patients who were able to
undergo a second transplant, experienced a 3-year 27% OS
starting after relapse. (Figure 1). No patients with AML
survived after relapse.
Conclusion: Although pre-emptive treatment of relapse in
the setting of MRD is felt to be ideal, it may not be feasible. In
our study, patients with MRD presented very early post-HCT
at a time when complications can be high and therapeutic
options are limited. Once MRD was detected, disease
progression was rapid limiting the chance to respond to
frontline immunotherapeutic options. Accordingly, there
was no survival advantage for pediatric patients with
leukemia whose relapse was detected as MRD compared to
overt disease. Given the poor outcomes of post-HCT relapse
and limited ability to treat relapse at the stage ofMRD, efforts
should focus on developing effective therapies for relapse
prevention by identifying those at highest risk of relapse as
candidates for novel methods to enhance efﬁcacy of alloHCT.395
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